MoonLake Immunotherapeutics (MLTX) Shares Outstanding (Weighted Average) (2020 - 2026)

MoonLake Immunotherapeutics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $71.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 12.71% year-over-year to $71.3 million; the TTM figure through Mar 2026 stood at $71.3 million (up 12.71% YoY), while the FY2025 annual figure was $64.5 million, up 2.53% from the prior year.
• Shares Outstanding (Weighted Average) was $71.3 million for Q1 2026 at MoonLake Immunotherapeutics, up from $64.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $71.3 million in Q1 2026 to a low of $5.0 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $50.6 million across 5 years, with a median of $62.6 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) surged 679.11% in 2023, then climbed 0.65% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $29.4 million in 2022, then jumped by 67.3% to $49.1 million in 2023, then rose by 27.99% to $62.9 million in 2024, then rose by 2.53% to $64.5 million in 2025, then rose by 10.56% to $71.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $71.3 million (Q1 2026), $64.5 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.